Arcus Biosciences falls 19.6% after $250 million share offering

What happened

Arcus Biosciences (RCUS) fell 19.6% on October 21, 2026, after the company launched and priced an underwritten public offering that would sell 14,285,715 shares at $17.50 per share for gross proceeds of $250 million. The stock’s decline came as Business Wire reported the offering and was followed by a PRNewsWire report that Kuehn Law, PLLC is investigating whether certain officers and directors breached fiduciary duties. The session’s selling left the market value at $2.78 billion.

How big was the move

The stock fell 19.6% on the day and fell 15.2% over the last five sessions, while the S&P 500 rose 0.6% on the day and rose 0.5% over five sessions. Trading volume was 2.6 times its 20-day average and the move was 4.8 times a typical daily move for this stock. Compared with its sector, the move was 19.3 percentage points worse than the Healthcare sector median. The company’s market sensitivity is indicated by a beta of 1.61, meaning the stock tends to move more than the market.

The technical picture

The stock traded below its moving averages, at 20.0% below its 20-day moving average, 28.0% below its 50-day moving average and 23.0% below its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend. The Relative Strength Index (14 days) stood at 28 (below 30, a level often called oversold). The share price was 39.8% below the 52-week high and fell 28.9% over one month; it fell 35.8% over three months but rose 9.3% over one year. Volatility measured 65% annualized over 60 days, higher than 60% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $117.0 million, a decline of 55.3% from a year earlier after growth of 67.4% one quarter earlier. Diluted earnings per share were $-3.93 and gross margin was 94.0% (a year earlier: 100.0%). The report shows very large margin and cash-flow metrics, with operating margin at 415.4% and free-cash-flow margin at 406.0%. Return on invested capital was 65.8% and the balance sheet held net cash of $36.0 million. Share count over one year increased by 18.4%, and the free-cash-flow yield was 17.1%.

Those figures paint a mixed picture. Revenue has swung sharply, reflecting a recent step-down from prior growth, while margin and cash-flow metrics are unusually high on the company’s reported basis. The increase in share count and the size of the new offering sharpen near-term dilution and capital-allocation questions for investors.

Earnings and analyst expectations

Arcus last reported on August 5, 2026, when earnings per share were $-0.72 against $-0.89 expected, 19.2% above estimates. The company has beaten estimates in one consecutive quarter and the average surprise over the last four reports was 8.2% above estimates. Typical two-day reaction after recent reports was that the stock fell 0.3%. The next report is scheduled for October 27, 2026.

Eighteen analysts cover the stock, the consensus rating is Buy and 83% of ratings are Buy or Strong Buy. The consensus price target was $40.00, 109.4% above the closing price. Those forecasts contrast with the market’s reaction to the offering and the legal inquiry, underscoring a divide between sell-side optimism on fundamentals and investor concerns about dilution and governance risk.

What to watch

• October 27, 2026: next earnings report
• Details of the underwritten public offering: 14,285,715 shares at $17.50 per share for gross proceeds of $250 million (reported by Business Wire)
• Status and developments in the investigation announced by Kuehn Law, PLLC (reported by PRNewsWire)
• Any company updates on use of proceeds, dilution or capital allocation following the offering
• Clinical data follow-ups or publications related to casdatifan (ARC-20 platform) and their market interpretation (reported by Seeking Alpha)